PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Current and future role of PCSK9 inhibitors in ASCVD prevention
    Greco, Antonio
    Capodanno, Davide
    FUTURE CARDIOLOGY, 2025, 21 (02) : 71 - 73
  • [22] Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives
    Tsouka, Aikaterini N.
    Tellis, Constantinos C.
    Tselepis, Alexandros D.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3622 - 3633
  • [23] PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
    Marco-Benedi, Victoria
    Sanchez-Hernandez, Rosa M.
    Diaz, Jose Luis
    Jarauta, Estibaliz
    Suarez-Tembra, Manuel
    Pinto, Xavier
    Morillas, Carlos
    Plana, Nuria
    Pedro-Botet, Juan
    Civeira, Fernando
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [24] The Evolving Future of PCSK9 Inhibitors
    Rosenson, Robert S.
    Hegele, Robert A.
    Fazio, Sergio
    Cannon, Christopher P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (03) : 314 - 329
  • [25] PCSK9 Inhibitors: The Evolving Future
    Jeswani, Bijay Mukesh
    Sharma, Shubhangi
    Rathore, Sawai Singh
    Nazir, Abubakar
    Bhatheja, Rohit
    Kapoor, Kapil
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [26] PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
    Jia, Xiaoming
    Al Rifai, Mahmoud
    Saeed, Anum
    Ballantyne, Christie M.
    Virani, Salim S.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 555 - 566
  • [27] Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
    Panagiotopoulou, Olga
    Chiesa, Scott T.
    Tousoulis, Dimitrios
    Charakida, Marietta
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (27) : 4494 - 4521
  • [28] PCSK9 inhibitors in clinical practice: Novel directions and new experiences
    Rallidis, Loukianos S.
    Skoumas, Ioannis
    Liberopoulos, Evangelos N.
    Vlachopoulos, Charalambos
    Kiouri, Estela
    Koutagiar, Iosif
    Anastasiou, Georgia
    Kosmas, Nikolaos
    Elisaf, Moses S.
    Tousoulis, Dimitrios
    Iliodromitis, Efstathios
    HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (04) : 241 - 245
  • [29] PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
    Di Bartolo, Belinda
    Scherer, Daniel J.
    Brown, Alex
    Psaltis, Peter J.
    Nicholls, Stephen J.
    BIODRUGS, 2017, 31 (03) : 167 - 174
  • [30] PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
    Belinda Di Bartolo
    Daniel J. Scherer
    Alex Brown
    Peter J. Psaltis
    Stephen J. Nicholls
    BioDrugs, 2017, 31 : 167 - 174
12345